Chonluten 20mg
Chonluten is a synthetic tripeptide bioregulator investigated for its tissue-specific role in modulating bronchopulmonary gene expression.
Mechanism
Chonluten is hypothesized to penetrate cellular compartments to modulate chromatin interactions and regulate the transcription of genes involved in cellular defense and respiratory structure, including c-Fos, HSP70, and superoxide dismutase.
Dosing
Preclinical and educational literature documents an initial experimental daily dose of 250 mcg administered via subcutaneous injection.
Reconstitution
Reconstituting a 20 mg vial with 3.0 mL of bacteriostatic water yields an approximate working concentration of 6.67 mg/mL (6,667 mcg/mL).
Storage
Store unmixed lyophilized vials at -20 °C protected from moisture, and keep the reconstituted solution refrigerated between 2 °C and 8 °C for up to 28 days without freezing.
Mix & measure Chonluten 20mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Chonluten 20mg
Vial strength → BAC water → target dose
Total doses in vial: 80.0
U-100 syringe: 100 units = 1 mL
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Weeks 1–2 | 250 mcg (1× daily) | ~3.75 units (0.0375 mL) |
| Weeks 3–4 | 500 mcg (1× daily) | ~7.5 units (0.075 mL) |
| Weeks 5–8 | 1,000 mcg (1× daily) | ~15 units (0.15 mL) |
| Weeks 9–16 | 1,500 mcg (1× daily) | ~22.5 units (0.225 mL) |
Reconstitution Steps
- 1
Draw 3.0 mL of bacteriostatic water into a sterile reconstitution syringe.
- 2
Carefully introduce the diluent by angling the stream down the interior glass wall of the Chonluten vial to minimize agitation and foaming.
- 3
Gently swirl or roll the vial between the palms until the lyophilized cake is fully dissolved, strictly avoiding vigorous shaking.
- 4
Affix a label indicating the reconstitution date and resulting concentration (~6.67 mg/mL), and store immediately in a refrigerator at 2–8 °C.
Supplies Needed
Peptide Vial
Lyophilized Chonluten peptide (20 mg per vial) for experimental use.
Insulin Syringes (U-100)
Calibrated 1 mL syringes utilized for accurate micro-volume measurement and daily administration.
Bacteriostatic Water
Sterile multi-dose diluent containing 0.9% benzyl alcohol used to reconstitute the peptide cake.
Alcohol Swabs
70% isopropyl alcohol prep pads for sanitizing the vial septum and the administration area.
Why researchers study it
Lung & bronchial support
Oxidative-stress & antioxidant research
Respiratory inflammation & immunity
Longevity & bioregulation
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Chonluten is a synthetic short-chain tripeptide composed of Glutamic acid, Aspartic acid, and Glycine (Glu-Asp-Gly or EDG), designated within Russian peptide bioregulator literature as T-34. Classified as a cytogen, it was developed by the Khavinson research group to emulate endogenous signaling within the bronchopulmonary and respiratory mucosal tissues. Because of its targeted sequence, it is frequently evaluated in experimental settings aimed at organ-specific cellular homeostasis. In preclinical research models, investigators assess Chonluten for its ability to regulate bronchial epithelial cell differentiation, diminish inflammatory cytokines, and support tissue resilience against environmental and oxidative stressors. It represents a synthetic counterpart to complex organ extracts, designed to offer high consistency for in vitro and in vivo laboratory investigations. Despite widespread exploration within specialized longevity and bioregulatory frameworks, Chonluten remains an unapproved investigational research peptide. Its pharmacokinetic behavior involves rapid enzymatic degradation typical of small tripeptides, and scientific data remains primarily confined to preclinical and animal studies.
References
- 1.Khavinson VK et al., PubMed, 2002 — Reviews of Khavinson short-peptide bioregulators (cytomax / cytogen class), including the bronchopulmonary tripeptide Chonluten (EDG)
- 2.Khavinson VK et al., Bulletin of Experimental Biology and Medicine, 2000 — Overview of Glu-Asp-Gly (EDG / Chonluten) and proposed tissue-specific activity in short-peptide bioregulator research
- 3.Anisimov VN et al., Biogerontology, 2003 — In-vitro and animal reports of short-peptide bioregulator effects on gene expression and anti-inflammatory signalling
- 4.Khavinson VK et al., Neuroendocrinology Letters, 2011 — Synthetic short peptides in cell senescence and epigenetic regulation of gene expression
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allGHRP-2 5mg
Synthetic hexapeptide secretagogue studied for pulsatile growth hormone induction via ghrelin receptor pathway agonism.
View ProtocolOrforglipron 6mg
An oral, non-peptide GLP-1 receptor agonist studied for daily metabolic regulation and body-weight management without injection.
View ProtocolTesamorelin 20mg
A stabilized GHRH analog investigated for triggering endogenous growth hormone pulses and targeted reduction of visceral adipose tissue.
View Protocol